Evidências científicas atualizadas sobre as vacinas para prevenção do SARS-COV-2 / Updated scientific evidence on vaccines for SARS-COV-2 prevention

Authors

  • Evelyn de Kenya Lins Prates
  • Fernanda Amparo Ribeiro
  • Edmar Araújo de Lima Filho
  • Camila Damiani de Matos
  • Clara Bucater Veado
  • Welsher Braga Ribeiro Chaves
  • Velton Braga Ribeiro Chaves
  • Pedro Henrique Sulz Marx
  • Fernanda Ramos Rangel

DOI:

https://doi.org/10.34119/bjhrv5n3-155

Keywords:

vacinas, coronavírus, prevenção primária.

Abstract

Os diversos laboratórios estão desenvolvendo vacinas para prevenção da infecção pelo SARS-CoV-2, conhecido como COVID-19.  O desenvolvimento de vacinas progride por meio de avaliação pré-clínica e três estágios clínicos distintos, ensaios de fase I que são elaborados para testar a segurança da vacina, embora a imunogenicidade também seja medida, ensaios de fase II que expandem o perfil de segurança e a avaliação da resposta imune em um número maior de participantes  e ensaios de fase III que são elaborados para determinar a eficácia na prevenção de um desfecho predefinido, geralmente doença confirmada por laboratório. Os estudos em animais para as vacinas de SARS-CoV-1 e MERS-CoV levantaram preocupações quanto ao aumento da doença com a vacinação, após o desafio com o vírus de tipo selvagem, alguns animais previamente vacinados desenvolveram anticorpos não neutralizantes e respostas de células Th2 que foram associadas à inflamação pulmonar eosinofílica. No entanto, parâmetros imunológicos específicos foram propostos para estudos em animais e humanos para reduzir o risco de aumento da doença com vacinas COVID-19.

References

World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020.

Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586:516.

Halstead SB, Katzelnick L. COVID-19 Vaccines: Should We Fear ADE? J Infect Dis 2020; 222:1946.

Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68.

Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26:6338.

Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020; 369:806.

Case JB, Rothlauf PW, Chen RE, et al. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe 2020; 28:465.

MacNeil JR, Su JR, Broder KR, et al.. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021. MMWR Morb Mortal Wkly Rep 2021.

Reynolds CJ, Pade C, Gibbons JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021.

Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.

Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep 2021.

Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 2021; 184:2348.

Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021.

Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA 2021; 325:780.

Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403.

Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021.

Hause AM, Gee J, Johnson T, et al. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021. MMWR Morb Mortal Wkly Rep 2021.

Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021.

Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021.

Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396:887.

Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; 21:637.

Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021.

Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. MMWR Morb Mortal Wkly Rep 2021; 70:639.

Published

2022-05-18

How to Cite

PRATES, E. de K. L.; RIBEIRO, F. A.; FILHO, E. A. de L.; MATOS, C. D. de; VEADO, C. B.; CHAVES, W. B. R.; CHAVES, V. B. R.; MARX, P. H. S.; RANGEL, F. R. Evidências científicas atualizadas sobre as vacinas para prevenção do SARS-COV-2 / Updated scientific evidence on vaccines for SARS-COV-2 prevention. Brazilian Journal of Health Review, [S. l.], v. 5, n. 3, p. 9833–9856, 2022. DOI: 10.34119/bjhrv5n3-155. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/48271. Acesso em: 28 mar. 2024.

Issue

Section

Original Papers